Investigational drug · Phase 3
Rezpegaldesleukin
Also called: NKTR-358, REZPEG, LY3471851, formerly
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
6
Any phase or sponsor naming "Rezpegaldesleukin"
First trial start
2023
Nov 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rezpegaldesleukin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate-to-Severe Atopic Dermatitis
- Moderate to Severe Atopic Dermatitis
- Alopecia Areata
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Alopecia areata · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Rezpegaldesleukin" as an intervention, largest first.
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Nektar TherapeuticsIndustry
NCT07690371 · 510 participants (planned) · Start Jun 29, 2026 · Primary completion May 2028
Drug: Rezpegaldesleukin; Placebo · For: Moderate-to-Severe Atopic Dermatitis
Sites: Phoenix, Arizona; North Little Rock, Arkansas; Fountain Valley, California · 20 sites in all
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisPivotal-lookingRecruiting
Nektar TherapeuticsIndustry
NCT07711418 · 510 participants (planned) · Start Aug 7, 2026 · Primary completion Jun 2028
Drug: Rezpegaldesleukin; Placebo · For: Moderate-to-Severe Atopic Dermatitis
Sites: Birmingham, Alabama; Oxnard, California; Palmdale, California · 13 sites in all
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisPivotal-lookingActive, not recruiting
Nektar TherapeuticsIndustry
NCT06136741 · 396 participants (planned) · Start Nov 15, 2023 · Primary completion May 6, 2025
Drug: Rezpegaldesleukin; Placebo · For: Moderate to Severe Atopic Dermatitis
Sites: Bryant, Arkansas; Fountain Valley, California; Los Angeles, California · 107 sites in all
- A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)Pivotal-lookingCompleted
Nektar TherapeuticsIndustry
NCT04433585 · 291 participants · Start Aug 19, 2020 · Primary completion Jan 10, 2023
Drug: LY3471851; Placebo · For: Systemic Lupus Erythematosus
Sites: La Jolla, California; Palm Desert, California; Stanford, California · 112 sites in all
Nektar TherapeuticsIndustry
NCT06340360 · 94 participants · Start Apr 2, 2024 · Primary completion Nov 26, 2025
Drug: Rezpegaldesleukin; Placebo · For: Alopecia Areata
Sites: Northridge, California; Atlanta, Georgia; Gurnee, Illinois · 26 sites in all
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT07142252 · 66 participants (planned) · Start May 14, 2026 · Primary completion May 25, 2028
Drug: Rezpegaldesleukin; Placebo · For: Type 1 Diabetes Mellitus
Sites: San Francisco, California; Aurora, Colorado; New Haven, Connecticut · 15 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Pretreatment with Feining Granules mitigates LPS-induced lung injury in mice: Pharmacological and serum metabolomics evidence.
Tan Z, Li K, Zhang L, et al. · J Ethnopharmacol 2027
- Lactiplantibacillus plantarum as a multifunctional probiotic for inflammatory bowel disease: Mechanisms, synbiotic strategies, and delivery systems.
Tao W, Liu W, Shi X, et al. · Synth Syst Biotechnol 2027
- First report of PLSA resistance gene sal(B) in multidrug-resistant foodborne Mammaliicoccus lentus: Molecular characterization and food safety implications.
Zhang F, Ma S, Gao J, et al. · Int J Food Microbiol 2027
- Evaluating reintegration effectiveness differently: A realist evaluation of sports programs in Belgian male prisons using the Capability Approach.
Libbrecht ML · Eval Program Plann 2027
- Preliminary evaluation of the performance of CHROMagarࡊ C.neoformans medium for the presumptive identification of the Cryptococcus neoformans/C. gattii species complex isolates.
Mpika DM, Bakana LM, Yobi DM, et al. · Diagn Microbiol Infect Dis 2027
- Characterization of a novel poxvirus associated with an epidermal keratinocytic dermatopathy in a captive population of the endangered Knysna seahorse Hippocampuscapensis.
Groff JM, Khrongsee P, Armien AG, et al. · Virology 2027
Also in development for Moderate-to-Severe Atopic Dermatitis
- SHR-1819Phase 38 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
- QLS12010Phase 23 trials
Qilu Pharmaceutical Co., Ltd. · Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA)
- JYP0061Experimental Drug GroupPhase 22 trials
Guangzhou JOYO Pharma Co., Ltd · Moderate-to-severe Atopic Dermatitis, Neuromyelitis Optica Spectrum Disorders
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.